BOULDER, CO / ACCESS Newswire / February 4, 2026 / Encision Inc. (OTC PINK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today reported its financial results for its 2026 fiscal third quarter.
Encision’s CEO Robert Fries commented, “The Company’s revenue has continued to decline principally because of procedures that were performed by surgical robots that have replaced our surgical procedures. Looking forward, we expect that this revenue decrease will continue. Gross profit margin percent decreased significantly in the third quarter because of a large increase to the inventory reserve. We are currently performing a restructuring and have reduced operating expenses substantially. This decrease will be recognized in the fourth quarter.”
Encision designs and markets a portfolio of high-performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures.
Encision Inc.
Condensed Statements of Operations
(unaudited)
|
|
Quarters ended |
Variance |
||||||||||||||
|
(in $ thousands)
|
Dec. 31, 2025 |
Sep. 30, 2025 |
($) |
(%) |
||||||||||||
|
Net sales
|
1,413 |
1,528 |
-115 |
-7.5 |
% |
|||||||||||
|
Cost of goods sold
|
870 |
831 |
39 |
4.7 |
% |
|||||||||||
|
Gross profit
|
543 |
697 |
-154 |
-22.1 |
% |
|||||||||||
|
Gross profit margin %
|
38.4 |
% |
45.6 |
% |
-7.2 |
% |
||||||||||
|
|
||||||||||||||||
|
Operating expenses
|
842 |
956 |
-114 |
-11.9 |
% |
|||||||||||
|
Operating income
|
(299 |
) |
(259 |
) |
(40 |
) |
-15.4 |
% |
||||||||
|
Operating margin %
|
-21.2 |
% |
-17.0 |
% |
-4.2 |
% |
||||||||||
|
|
||||||||||||||||
|
Interest and other expense, net
|
(15 |
) |
(9 |
) |
-6 |
|||||||||||
|
Net loss
|
(314 |
) |
(268 |
) |
(46 |
) |
-17.2 |
% |
||||||||
CONTACT: Mala Ray, Encision Inc, 303-444-2600, mray@encision.com
SOURCE: Encision, Inc.
View the original press release on ACCESS Newswire
Investment supports Flow Technology's ability to help pharmaceutical and biotechnology manufacturers expand production and navigate…
Learn how to diversify your 401(k) and hedge against inflation through this new guide released…
LONDON, UK / ACCESS Newswire / September 7, 2026 / The Company announces that on…
LONDON, UK / ACCESS Newswire / September 7, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow"…
NORTH PALM BEACH, FL / ACCESS Newswire / September 6, 2026 / As national discussion…
The review and trust verification platform WebVouch surpasses 147,000 verified reviews across gaming services, digital…
